Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT04504162 |
Other study ID # |
HFJiang-005 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 1, 2020 |
Est. completion date |
July 31, 2022 |
Study information
Verified date |
July 2020 |
Source |
Shanghai Mental Health Center |
Contact |
Haifeng Jiang, Dr. |
Phone |
(86)-021-64906315 |
Email |
dragonjhf[@]hotmail.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
This study will establish a sedative and hypnotics iatrogenic addiction risk monitoring
network composed of 4 psychiatric hospitals in Shanghai through standardized data
construction of outpatient prescription data and personnel training. Develop a
sedative-hypnotic addiction risk prediction tool based on patient prescription data, and use
independent in-operation outpatient prescription data for verification, and carry out
clinical application promotion.
Description:
This study is a longitudinal analysis of the outpatient prescription data of psychiatric
hospitals. It includes two aspects: 1) Develop evaluation methods for the risk of
sedative-hypnotic addiction in psychiatric hospitals; 2) Construct a predictive model for the
risk of iatrogenic addiction to sedative-hypnotics.
Step 1. Export all sedative hypnotic prescription information from the outpatient medical
record system of Shanghai Psychiatric Hospital.
The data range is from January 1, 2019 to December 31, 2020. The data items that need to be
exported include: patient identification information, gender, age, diagnosis, prescription
drug name, drug use method, total dose, time , and the physician number of the prescription.
Generate a unique patient number based on identification information (such as ID number), and
merge all prescription information and electronic medical records of the same patient during
the study period.
Step 2. Identify patients at risk of addiction to sedative hypnotics. This study defines the
risk of addiction to sedatives and hypnotics when the outpatients appear "double off-label
prescriptions". The standard of "double off-label prescriptions" is: the highest daily
average dose of prescriptions obtained by patients>60 mg diazepam equivalent milligrams, and
the number of consecutive prescription days>120 days. Firstly, mark whether the patient has a
prescription that exceeds the specification range (over indication, over daily dose range,
over treatment course) during the study period. Secondly, the analysis data set is further
converted and labeled, including: all benzodiazepine doses are converted into diazepam
equivalents according to the "Benzazepine Dose Conversion Table". Calculate the "average
daily prescription dose" for each patient: add up the prescriptions of benzodiazepines to get
the total prescription, and divide by the number of days to get the average daily
prescription dose. Finally, calculate the monthly or annual cases or proportion of "double
off-label prescriptions" patients who are at risk of addiction to sedatives and hypnotics.
Step 3.Establish a risk prediction model for iatrogenic addiction to sedative and hypnotics
in psychiatric hospitals.
Use correlation analysis or machine learning methods to explore the formation trajectory of
the "double off-label" pattern of sedative hypnotic prescriptions, and build a predictive
model that can predict the formation of the "double off-label" pattern. Use a subset of
prescription data to identify patients with status of "double off-label", then evaluate and
review them to confirm the addiction status of sedatives and hypnotics. Use the validation
subset to verify and improve the addiction risk prediction model based on the training data
set.